Touchlight and Pfizer to use dbDNA to manufacture mRNA-based vaccines, therapeutics and gene therapies

Published: 6-Jul-2022

Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapies

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, announces a non-exclusive patent license agreement with Pfizer.

Under the license agreement, Pfizer gains rights to Touchlight’s enzymatic doggybone DNA (dbDNA) patent portfolio for worldwide use in Pfizer’s manufacture and commercialisation of its messenger RNA-based vaccines, therapeutics and gene therapies. Touchlight will receive an upfront payment, as well as clinical and commercial milestone payments and royalties upon commercialisation.

Touchlight’s patented dbDNA technology produces a minimal, linear, double stranded, covalently closed DNA vector through an enzymatic manufacturing process. dbDNA is uniquely positioned for the rapid, synthetic, and scalable manufacture of GMP DNA using a small, simple footprint.

The technology can manufacture genes >20kb and accommodate sequences typically unstable as plasmid DNA in E. coli, such as those found in viral vector and mRNA production. In addition to mRNA vaccines, it is ideally suited for the development of DNA vaccines, advanced therapies and more.

Jonny Ohlson, Founder and Executive Chair, Touchlight, commented: “We are delighted to establish this agreement with Pfizer to license our mRNA manufacturing platform. This agreement is an example of our technology’s potential to enable companies across the genetic medicine sector to simplify and accelerate DNA manufacturing through the clinic and towards commercialisation.”

Financial terms are not disclosed.

You may also like